SHRM.CN - Champignon Brands Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.8900
0.0000 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.8900
Open0.0000
Bid0.8000 x N/A
Ask0.8000 x N/A
Day's Range0.8900 - 0.8900
52 Week Range0.1800 - 2.4000
Volume0
Avg. Volume1,862,754
Market Cap70.541M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Champignon Announces Regulatory Review

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”). The review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company. Ensuring fulsome and timely disclosure is vital to the success of our Company, and development of our industry with the investing public.

  • CNW Group

    IIROC Trading Halt - SHRM

    VANCOUVER, BC , June 22, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Champignon Brands Inc. CSE Symbol: SHRM (all issues) Reason: CTO Halt Time (ET): 8:00 AM IIROC can make a ...

  • GlobeNewswire

    REPEAT - Champignon’s Dr. McIntyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Journals

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (MDD) while demonstrating rapid onset efficacy and safety of its treatment processes. The Company invites both current and prospective shareholders to review the Peer Reviewed Studies using applicable databases.

  • GlobeNewswire

    Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Journals

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (MDD) while demonstrating rapid onset efficacy and safety of its treatment processes. The Company invites both current and prospective shareholders to review the Peer Reviewed Studies using applicable databases.

  • GlobeNewswire

    REPEAT - Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiatives to position the Company as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder (“PTSD”), and substance-use disorders (“SUD”) via the clinical delivery of ketamine and ketamine-derivatives. Closing its previously announced CAD $15,000,375 bought-deal private placement co-lead by Canaccord Genuity Corp. and Eight Capital, including the exercise in full of the option granted to the Underwriters.

  • GlobeNewswire

    Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiatives to position the Company as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder (“PTSD”), and substance-use disorders (“SUD”) via the clinical delivery of ketamine and ketamine-derivatives. Closing its previously announced CAD $15,000,375 bought-deal private placement co-lead by Canaccord Genuity Corp. and Eight Capital, including the exercise in full of the option granted to the Underwriters.

  • CNW Group

    IIROC Trade Resumption - SHRM

    IIROC Trade Resumption - SHRM

  • GlobeNewswire

    Champignon Announces Closing of $15 Million Bought Deal Private Placement

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce the closing of its previously announced "bought deal" private placement (the "Offering") of units of the Company ("Units") for aggregate gross proceeds of $15,000,375 which includes the full exercise of the option granted to the Underwriters (as defined below). Each Unit is comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole warrant, a "Warrant").

  • GlobeNewswire

    REPEAT - Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. Dalriada, a leading contract research organization (CRO) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms.

  • GlobeNewswire

    Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. Dalriada, a leading contract research organization (CRO) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms.

  • GlobeNewswire

    Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing Services

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announces that certain shareholders have agreed to a voluntary resale restriction period covering 17,840,000 common shares extending the period of time before the shares become free trading to July 15, 2020. The Company also announces that it has engaged Gold Standard Media, LLC (“GSM”) to provide marketing and consulting services to raise public awareness of the Company, with a specific emphasis on the Company’s North American clinical expansion. GSM is a limited liability company existing under the laws of the State of Texas with an office at 1102 S. Austin Ave, #110-283, Georgetown, Texas, USA.

  • Baystreet

    Stocks in play: EGF Theramed Health Corp.

    Announced that it closed on the joint venture transaction with Green Parrot Labs Corp., previously announced ...

  • GlobeNewswire

    REPEAT - Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business executives and thought leaders with successful track records of advancing research and awareness within the arena of depression, post-traumatic stress disorder (“PTSD”), and substance abuse disorders (“DPS”). To this accord, Champignon is pleased to appoint Dr. Bill Wilkerson, LL.D. (Hon) to its board of directors. An executive equipped with extensive service in business, government, broadcasting, the arts, and corporate crisis management, Dr. Wilkerson is an 8-time award-winning pioneer in workplace mental health.

  • GlobeNewswire

    Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business executives and thought leaders with successful track records of advancing research and awareness within the arena of depression, post-traumatic stress disorder (“PTSD”), and substance abuse disorders (“DPS”). To this accord, Champignon is pleased to appoint Dr. Bill Wilkerson, LL.D. (Hon) to its board of directors. An executive equipped with extensive service in business, government, broadcasting, the arts, and corporate crisis management, Dr. Wilkerson is an 8-time award-winning pioneer in workplace mental health.

  • GlobeNewswire

    REPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and Health Professionals

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to sponsor TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders (the “TheraPsil Coalition”) seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress. Operating at highest standards of clinical competence and ethical integrity, the TheraPsil coalition is starting in 2020 with seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress.

  • GlobeNewswire

    Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and Health Professionals

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to sponsor TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders (the “TheraPsil Coalition”) seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress. Operating at highest standards of clinical competence and ethical integrity, the TheraPsil coalition is starting in 2020 with seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress.

  • GlobeNewswire

    Champignon Expands to U.S., To Acquire California Based Ketamine Centre – Wellness Clinic of Orange County

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine is pleased to announce that it has executed a term sheet (the “Term Sheet”) with California, U.S. based Wellness Clinic of Orange County Inc. (the “Wellness Clinic”) further advancing the Company’s North American clinical expansion. The Wellness Clinic owns and operates a state-of-the-art ketamine infusion treatment center located within the Mission Hospital’s Laguna Beach campus.

  • CNW Group

    Champignon Announces $10,000,000 Bought Deal Private Placement

    VANCOUVER, May 11, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE:SHRM.CN - News) (FWB:496.F - News), is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("Canaccord Genuity") and Eight Capital ("Eight" and together with Canaccord Genuity, the "Co-Lead Underwriters"), to purchase, on a bought deal private placement basis, 11,765,000 units of the Company (the "Units") at a price of $0.85 per Unit (the "Issue Price") amounting to aggregate gross proceeds of $10,000,250 (the "Offering"). Each Unit shall be comprised of one common share of the Company (a "Common Share") and one half of one common share purchase warrant of the Company (each whole warrant, a "Warrant").

  • GlobeNewswire

    REPEAT - Champignon Appoints Dr. Roger McIntyre as Chief Executive Officer

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to announce that it has appointed Dr. Roger McIntyre as Chief Executive Officer. Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

  • GlobeNewswire

    Champignon Appoints Dr. Roger McIntyre as Chief Executive Officer

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to announce that it has appointed Dr. Roger McIntyre as Chief Executive Officer. Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

  • GlobeNewswire

    REPEAT - Champignon Appoints Pat McCutcheon to Board of Directors

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce the appointment of Pat McCutcheon to its board of directors effective immediately. Mr. McCutcheon is currently Chief Executive Officer of one of the leading global cannabis companies,  MediPharm Labs Corp. (“MediPharm”) (LABS.TO). A true visionary in the emerging global cannabis industry, Mr. McCutcheon initially founded MediPharm after identifying an important, overlooked segment of the burgeoning cannabis market to create the first pure-play cannabis company focused solely on extraction and API manufacturing.

  • GlobeNewswire

    Champignon Appoints Pat McCutcheon to Board of Directors

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce the appointment of Pat McCutcheon to its board of directors effective immediately. Mr. McCutcheon is currently Chief Executive Officer of one of the leading global cannabis companies,  MediPharm Labs Corp. (“MediPharm”) (LABS.TO). A true visionary in the emerging global cannabis industry, Mr. McCutcheon initially founded MediPharm after identifying an important, overlooked segment of the burgeoning cannabis market to create the first pure-play cannabis company focused solely on extraction and API manufacturing.

  • GlobeNewswire

    Champignon Forms North American Clinical Expansion Committee

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, has advanced its North American new clinical entity (NCE) expansion stratagem via the formation of a dedicated planning committee (the “Committee”). The Committee has been mandated with accelerating the Company’s entry into the U.S., where it plans to open and/or acquire a minimum of five NCEs during 2020. Champignon continues to conduct discussions with revenue generating clinics located in California, New York, Pennsylvania, Texas, Florida and Missouri.

  • GlobeNewswire

    Le traitement à base de kétamine de Champignon sera distribué par une importante chaîne de pharmacie canadienne et la compagnie annonce la clôture de la transaction d'AltMed

    VANCOUVER, Colombie-Britannique, April 30, 2020 -- Champignon Brands Inc. (« Champignon » ou la « société ») (CSE : SHRM) (FWB : 496) (OTCQB : SHRMF), une société des sciences.

  • GlobeNewswire

    Champignon Ketamine Treatment to be Dispensed by Major Canadian Pharmacy Chain; Closes AltMed

    Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to strengthen its vertically integrated psychedelic medicine ecosystem via the acceleration of its ketamine topicals prescription fulfillment capabilities. The Company is pleased to announce the addition of central fill and compounding infrastructure for its proprietary ketamine formulations via a location at one of Canada’s leading retail pharmacy chains (the “Pharmacy”), as well as the dispensing of its products throughout the Pharmacy’s network.